- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04293523
Un estudio de 48 meses para evaluar la eficacia a largo plazo de Elocta en la salud de las articulaciones (A-MORE)
Un estudio observacional multicéntrico de 48 meses para evaluar la eficacia a largo plazo de Elocta en la salud de las articulaciones
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
Descripción general del estudio
Descripción detallada
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.
Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.
The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania
- Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
-
Bonn, Alemania
- Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Frankfurt, Alemania
- Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
-
Frankfurt, Alemania
- Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
-
Hamburg, Alemania
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Hanover, Alemania
- Medizinische Hochschule Hannover
-
Hanover, Alemania
- Werlhof-Institut für Hämostaseologie GmbH
-
Heidelberg, Alemania
- SRH-Klinikum Heidelberg
-
Mörfelden-Walldorf, Alemania
- HZRM Hämöphilie Zentrum Rhein Main
-
München, Alemania
- Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
-
-
-
-
-
Riyadh, Arabia Saudita
- Dr Suliman Al Habib Hospital Riyadh
-
Riyadh, Arabia Saudita
- King Faisal Specialised Hospital, KFSH Riyadh, Children
-
Riyadh, Arabia Saudita
- King Faisal Specialist Hospital KFSH, Adults
-
Riyadh, Arabia Saudita
- Riyadh Military Hospital (P.S.M.C)
-
-
-
-
-
Brno, Chequia
- University Hospital Brno
-
Ostrava, Chequia
- University Hospital Ostrava
-
Prague, Chequia
- Dept. of Pediatric Haematology and Oncology, University Hospital Motol
-
-
-
-
-
Ljubljana, Eslovenia
- University Medical Centre Ljubljana Division of Paediatrics
-
-
-
-
-
Barcelona, España
- Sant Johan De Deu
-
Barcelona, España
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, España
- Hospital Vall d'Hebron
-
Cruces, España
- Hospital Universitario Cruces
-
Donostia / San Sebastian, España
- Hospital Universitario Donostia
-
Murcia, España
- Hospital Virgen de la Arrixaca
-
Málaga, España
- Hospital Universitario Carlos Haya
-
Navarro, España
- Complejo Hospitalario de Navarra
-
Oviedo, España
- Hospital Universitario Central de Asturias (HUCA)
-
Palma de Mallorca, España
- Hospital Universitario Son Espases
-
Seville, España
- Hospital Universitario Virgen del Rocío
-
Vigo, España
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Tallinn, Estonia
- Lastehaigla, Tallinn (Tallinn Children´s Hospital)
-
Tallinn, Estonia
- The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
-
-
-
-
-
Helsinki, Finlandia
- Helsinki University Central Hospital, New Children Hospital
-
Turku, Finlandia
- Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
-
-
-
-
-
Thessaloniki, Grecia
- Ippokrateio Hospital Thessaloniki (adult department)
-
Thessaloniki, Grecia
- Ippokrateio Hospital Thessaloniki (pediatric department)
-
-
-
-
-
Bari, Italia
- University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
-
Cesena, Italia
- AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
-
Genova, Italia
- Giannina Gaslini Institute
-
Milan, Italia
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Parma, Italia
- University Hospital of Parma, AOUP, Haemophilia Center
-
Rome, Italia
- Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
-
Torino, Italia
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
-
-
-
-
-
Muscat, Omán
- The Royal Hospital
-
-
-
-
-
Groningen, Países Bajos
- University Medical Center Groningen/UMCG
-
-
-
-
-
Canterbury, Reino Unido
- East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
-
London, Reino Unido
- Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
-
-
-
-
-
Gothenburg, Suecia
- Hematologimottagning Sahlgrenska
-
Malmö, Suecia
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
-
-
-
-
-
Bern, Suiza
- Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
-
Lausanne, Suiza
- Service et Laboratoire central d'hématologie, Adults
-
Sankt Gallen, Suiza
- Zentrum für Labormedizin
-
Zurich, Suiza
- Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.
Descripción
Inclusion Criteria:
- Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
- Have a diagnosis of haemophilia A
- At enrolment on prophylactic treatment with Elocta, independent of participation in the study
Exclusion Criteria:
- Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
- Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Hemophilia A patients
All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice. |
Extended half-life factor VIII product
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Joint health: Target joint development
Periodo de tiempo: 48 months
|
Number of target joints |
48 months
|
|
Joint health: Target joint resolution
Periodo de tiempo: 48 months
|
Number of resolved target joints |
48 months
|
|
Joint health: Target joint recurrence
Periodo de tiempo: 48 months
|
Number of recurring target joints |
48 months
|
|
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Periodo de tiempo: 48 months
|
Number of joint bleeding events per year, for treated bleeds |
48 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Periodo de tiempo: 48 months
|
The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome. |
48 months
|
|
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Periodo de tiempo: 48 months
|
The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles. The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome. |
48 months
|
|
Joint and physical evaluation for elbows, knees and ankles.
Periodo de tiempo: 48 months
|
The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome. |
48 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Periodo de tiempo: 48 months
|
Number of bleeding events per year, for treated bleeds |
48 months
|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Periodo de tiempo: 48 months
|
Number of bleeding events per year, for all bleeds |
48 months
|
|
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Periodo de tiempo: 48 months
|
Percentage (%) of study population with zero (0) joint bleeds |
48 months
|
|
Effectiveness of Elocta: Work productivity and impairment
Periodo de tiempo: 48 months
|
Assessed by WPAI-SHP questionnaire |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Periodo de tiempo: 48 months
|
Assessed by Haemo-QoL/Haem-A-QoL questionnaire |
48 months
|
|
Effectiveness of Elocta: Physical activity level
Periodo de tiempo: 48 months
|
Assessed by the Saltin-Grimby scale |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Periodo de tiempo: 48 months
|
Assessed by EQ-5D-5L/EQ-5D-Y questionnaire |
48 months
|
|
Effectiveness of Elocta: Severity of joint health
Periodo de tiempo: 48 months
|
Assessed by Patient Global Impression of Severity of Joint Health questionnaire |
48 months
|
|
Effectiveness of Elocta: FVIII plasma levels
Periodo de tiempo: 48 months
|
Percentage (%) of FVIII plasma level |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Periodo de tiempo: 48 months
|
Assessed by medication dose |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Periodo de tiempo: 48 months
|
Assessed by total number of exposure days per medication |
48 months
|
|
Usage of Elocta: Annualised injection frequency per subject
Periodo de tiempo: 48 months
|
Assessed by prescription |
48 months
|
|
Usage of Elocta: Annualised factor consumption per subject
Periodo de tiempo: 48 months
|
Assessed by prescription [IU/kg] |
48 months
|
|
Usage of Elocta: Adherence
Periodo de tiempo: 48 months
|
Investigator assessed (Percentage (%)) |
48 months
|
|
Exploratory Objective
Periodo de tiempo: 48 months
|
Influence of different Elocta prophylaxis regimens on long term joint health |
48 months
|
|
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Periodo de tiempo: 48 months
|
Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level |
48 months
|
|
Exploratory Objective: Explore adherence to prescribed treatment regimen
Periodo de tiempo: 48 months
|
florio HAEMO captured treatment adherence scores |
48 months
|
|
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Periodo de tiempo: 48 months
|
florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps) |
48 months
|
|
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Periodo de tiempo: 48 months
|
florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels |
48 months
|
|
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Periodo de tiempo: 48 months
|
florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Target joint development, resolution and recurrence |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Annualised joint bleeding rate (AJBR) for treated bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Ultrasound (HEAD-US) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Clinical joint scoring (HJHS) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Occurrence of zero (0) joint bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Quality of Life assessed by Haemo-QoL/Haem-A-QoL |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months
|
Physical activity level assessed by the Saltin-Grimby scale |
48 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Study Physician, Swedish Orphan Biovitrum
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Genéticas Congénitas
- Enfermedades hematológicas
- Trastornos de la coagulación de la sangre
- Trastornos hemorrágicos
- Trastornos de la coagulación de la sangre, hereditarios
- Trastornos de proteínas de coagulación
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades hemic y linfáticas
- Hemofilia A
- proteína de fusión factor VIII-Fc
Otros números de identificación del estudio
- Sobi.Elocta-005
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .